Therapeutic strategies targeting NOX4 or the ROS it generates should take into consideration TP53 mutation status, as NOX4 may provide patient survival benefits in the presence of WT-p53 but may represent a worthwhile target in advanced cancers with mutated p53. Here, NOX4 is linked to cancer.